View all news

Elizabeth Blackwell Institute Advisor on Business Development

Richard Seabrook

Dr Richard Seabrook

22 January 2018

The Elizabeth Blackwell Institute for Health Research (EBI) welcomed Dr Richard Seabrook MBA, as its Advisor on Business Development.

Dr Seabrook will provide leadership to support the growth of partnerships and alliances with industry across the health arena at the University of Bristol. He will lead the EBI’s engagement with small and medium-sized enterprises, investors and major companies for the translation of new health interventions. He will also focus on identifying new opportunities to translate fundamental health research across the University into commercial impact.

Dr Seabrook’s previous roles include Head of Business Development at the Wellcome Trust, where he saw over 30 of its programmes progress to the clinic or to product approval stage and was the architect of the Trust’s £200-million Seeding Drug Discovery fund. He has also been a strategic advisor for the Royal Academy of Engineering and the Engineering and Physical Sciences Research Council. Currently he runs his own advisory business, 360Biomedical, and is a Senior Advisor for the Medicines Discovery Catapult and the Wellcome Trust. 

Some examples of outcomes from the work led by Dr Seabrook include the discovery of an experimental synthetic antimalarial drug KAE609, cancer drug Pan-Raf inhibitor, development of candidate drugs to treat serious bacterial infections (Plazomicin and Ridinilazole) and development of Xanamem (candidate to treat Alzheimer’s disease). Other achievements include a range of phase 2 studies that are currently in progress, commercialisation of the molecular diagnostic platform SAMBA, CardioRep and McGrath5 larygnoscope, vaccine and global health developments. 

Dr Seabrook said: ‘I’m very much looking forward to working with the research and clinical faculties here at Bristol. I am sure collectively through our translational efforts we will both advance important science and create new health interventions of commercial or global health potential.’ 

Edit this page